Neuropeptides in sepsis: From brain pathology to systemic inflammation

Septic encephalopathy is frequently diagnosed in critically ill patients and in up to 70% of patients with severe systemic infection [19]. The syndrome is defined by diffuse cerebral dysfunction or structural abnormalities attributed to the effects of systemic infection, rather than a direct central nervous system cause. The clinical characteristics can range from mild delirium to deep coma, but patients are often medically sedated making the diagnosis difficult. Any manifestation, however, is specific and markers of disease are lacking [43]. Sepsis survivors present long term cognitive impairment, including alterations of memory, attention and concentration [10,54]. Here, we propose that neuropeptides may play a key role in septic encephalopathy, leading to a vicious circle characterized by brain disease and systemic inflammation.

Palavras-chave

Sepsis, Encephalopathy, Neuropeptides

URI

https://observatorio.fm.usp.br/handle/OPI/3923

Referências

Ang SF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024535
Barrocas AM, 1999, IMMUNOPHARMACOLOGY, V41, P131, DOI 10.1016/S0162-3109(98)00064-2
BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531
Beer S, 2002, CRIT CARE MED, V30, P1794, DOI 10.1097/00003246-200208000-00020
Bhatia M, 2010, ANTIOXID REDOX SIGN, V12, P1191, DOI 10.1089/ars.2009.2927
Bourne RS, 2008, CRIT CARE, V12, DOI 10.1186/cc6871
Boyko Y, 2012, ACTA ANAESTH SCAND, V56, P950, DOI 10.1111/j.1399-6576.2012.02672.x
Carrillo-Vico A, 2005, J PINEAL RES, V39, P400, DOI 10.1111/j.1600-079X.2005.00265.x
CATANIA A, 1993, ENDOCR REV, V14, P564, DOI 10.1210/er.14.5.564
Comim CM, 2009, CURR NEUROVASC RES, V6, P194
Cooper AB, 2000, CHEST, V117, P809, DOI 10.1378/chest.117.3.809
Doi K, 2008, KIDNEY INT, V73, P1266, DOI 10.1038/ki.2008.97
Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R
Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753
Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155
Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
GARRIDO JJ, 1992, REGUL PEPTIDES, V41, P27
Gitto E, 2001, PEDIATR RES, V50, P756, DOI 10.1203/00006450-200112000-00021
Gofton TE, 2012, NAT REV NEUROL, V8, P557, DOI 10.1038/nrneurol.2012.183
Grimmelikhuijzen CJP, 2012, REGUL PEPTIDES, V177, pS6, DOI 10.1016/j.regpep.2012.05.001
Hashimoto Hirofumi, 2012, Pathophysiology, V19, P283, DOI 10.1016/j.pathophys.2012.07.005
Hegde A, 2007, J LEUKOCYTE BIOL, V82, P678, DOI 10.1189/jlb.0407217
Heinrichs M, 2009, FRONT NEUROENDOCRIN, V30, P548, DOI 10.1016/j.yfrne.2009.05.005
Holst B, 2005, MOL ENDOCRINOL, V19, P2400, DOI 10.1210/me.2005-0059
Hoyer D, 2012, CHEM BIODIVERS, V9, P2367, DOI 10.1002/cbdv.201200288
Kamdar Biren B, 2012, J Intensive Care Med, V27, P97, DOI 10.1177/0885066610394322
Kern A, 2012, NEURON, V73, P317, DOI 10.1016/j.neuron.2011.10.038
Kyriacou CP, 2010, TRENDS COGN SCI, V14, P259, DOI 10.1016/j.tics.2010.03.007
Lasaga M, 2011, PEPTIDES, V32, P1972, DOI 10.1016/j.peptides.2011.07.009
LUNDEBERG T, 1994, NEUROSCI LETT, V170, P153, DOI 10.1016/0304-3940(94)90262-3
Maniam J, 2012, NEUROPHARMACOLOGY, V63, P97, DOI 10.1016/j.neuropharm.2012.04.017
Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
Mustain WC, 2011, CURR OPIN ENDOCRINOL, V18, P75, DOI 10.1097/MED.0b013e3283419052
Myers MG, 2012, NATURE, V491, P357, DOI 10.1038/nature11705
Ng SW, 2008, J LEUKOCYTE BIOL, V83, P288, DOI 10.1189/jlb.0807575
O'Callaghan EK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047087
OLIVEIRAPELEGRI.GR, 2012, NEUROIMMUNOMODULAT, V20, P65
Oliveira-Pelegrin GR, 2010, PEPTIDES, V31, P1847, DOI 10.1016/j.peptides.2010.06.031
PALMBLAD J, 1979, PSYCHOSOM MED, V41, P273
Paskaloglu K, 2004, LIFE SCI, V74, P1093, DOI 10.1016/j.lfs.2003.07.038
Petervari E, 2011, REGUL PEPTIDES, V166, P105, DOI 10.1016/j.regpep.2010.10.002
Piliponsky AM, 2008, NAT MED, V14, P392, DOI 10.1038/nm1738
Pytel P, 2009, CURR OPIN NEUROL, V22, P283, DOI 10.1097/WCO.0b013e32832b3101
Quera Salva M A, 2011, Curr Pharm Des, V17, P1459
Rosin DL, 2003, J COMP NEUROL, V465, P593, DOI 10.1002/ene.10860
Sack RL, 1997, SLEEP, V20, P908
Sakurai T, 2010, ANN NY ACAD SCI, V1200, P149, DOI 10.1111/j.1749-6632.2010.05513.x
Salas RE, 2008, CRIT CARE CLIN, V24, P461, DOI 10.1016/j.ccc.2008.02.006
Semmler A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-38
SEWERYNEK E, 1995, EUR J PHARM-ENVIRON, V293, P327, DOI 10.1016/S0014-2999(95)80090-5
Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004
Srinivasan Venkataramanujam, 2012, Recent Pat Endocr Metab Immune Drug Discov, V6, P30
Stoop R, 2012, NEURON, V76, P142, DOI 10.1016/j.neuron.2012.09.025
Streck EL, 2008, NEUROCHEM RES, V33, P2171, DOI 10.1007/s11064-008-9671-3
Tsujino N, 2009, PHARMACOL REV, V61, P162, DOI 10.1124/pr.109.001321
UMBRIACO D, 1990, J COMP NEUROL, V291, P167, DOI 10.1002/cne.902910202
van den Pol AN, 2012, NEURON, V76, P98, DOI 10.1016/j.neuron.2012.09.014
Weinhouse GL, 2009, CRIT CARE, V13, DOI 10.1186/cc8131
Williams KW, 2012, NAT NEUROSCI, V15, P1350, DOI 10.1038/nn.3217
Windle RJ, 1997, ENDOCRINOLOGY, V138, P2829, DOI 10.1210/en.138.7.2829
Wu JY, 2008, J PINEAL RES, V45, P106, DOI 10.1111/j.1600-079X.2008.00567.x
YANG J, 1994, SPINE, V19, P867, DOI 10.1097/00007632-199404150-00001
Yeo GSH, 2012, NAT NEUROSCI, V15, P1343, DOI 10.1038/nn.3211
Yerer MB, 2003, J PINEAL RES, V35, P138, DOI 10.1034/j.1600-079X.2003.00062.x
Zhang HL, 2007, J IMMUNOL, V179, P4153

Coleções

Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/51

Página do item completo